Studies show that ivermectin 'has no effect' on the treatment of the new corona



Vaccination of the new coronavirus infection (COVID-19) has started in Japan as well, and along with this, voices of 'anti-vaccine groups' who oppose vaccination are being heard in various places. .. One of the therapeutic agents recommended by such anti-vaccine groups as a therapeutic agent for COVID-19 is

ivermectin . A doctor-led clinical trial is being conducted at the Kitasato Institute on the effects of ivermectin, and some doctors claim that it works well for mildly ill patients (of COVID-19), but the latest research shows that COVID-19 The treatment has been shown to have 'no effect'.

Hiltzik: Ivermectin shows'no effect' as COVID treatment --Los Angeles Times
https://www.latimes.com/business/story/2021-08-11/ivermectin-no-effect-covid

Vaccination with the new coronavirus is already underway in some countries and regions, but the current situation is that large-scale vaccination in low- and middle-income countries 'will take a long time.' In the meantime, medical systems around the world are being squeezed, and the number of COVID-19 patients continues to increase, so there is a worldwide need to devise ways to reduce inpatients by means other than vaccines.

Together Trial was launched under such circumstances, and this is a test to confirm 'whether there is any existing drug that has a promising effect on COVID-19'. A study of ivermectin in this Together Trial revealed that it had 'no effect.'

Together Trial is a large-scale exam conducted in Brazil under the supervision of McMaster University in Canada. Edward Mills, one of the lead researchers in the study, published the results of the ivermectin study in the Together Trial at a symposium hosted by the National Institutes of Health (NIH) on August 6, 2021.



Approximately 1,500 COVID-19 patients participated in the Together Trial study of ivermectin, and were widely administered regardless of whether the patients needed a long-term difference in the emergency room or hospitalization. it was done. Tests have shown that ivermectin 'has no effect at all,' Mills said.

There were two specific study methods during the study period, and the effect of ivermectin on a single dose was tested at the beginning of the study, but after that, '400 micrograms of ivermectin per kg of patient's body weight was tested once a day. It has been changed to 'administer once for 3 days'. Half of the subjects were given placebo tablets, and as a result of the analysis, there was no difference in clinical results.

The results of this study on ivermectin in the Together Trial have not been published as a formal treatise and have not been peer-reviewed.

However, the Together Trial has shown in a peer-reviewed research paper that the antimalarial hydroxychloroquine, which former President Donald Trump has previously advertised as a treatment for COVID-19, has no significant therapeutic effect.

Ivermectin attracted attention as a therapeutic drug for COVID-19 in a paper published in 2020 by an Australian researcher, 'to some extent effective against the new coronavirus (SARS-CoV-2). This is because it was reported that 'it showed sex.' However, this study used levels of ivermectin that could not be administered to the human body.



Ivermectin has gained support from anti-vaccine people and conspiracy theorists, but Mills said, 'Clinicians who administer ivermectin in the field, including myself, have been exposed to more than enough criticism. People working in the medical field are threatening themselves and their families and being disgraced, 'said conspiracy theorists and anti-vaccines who took ivermectin. It reveals the fact that the doctors who went there have faced difficulties.

On the other hand, based on the results of this study, he said that if he continues to support ivermectin, he will be exposed to further criticism 'it will be inevitable', and as the test results show, ivermectin will be used for the treatment of COVID-19. Reiterates that it has no effect.

in Science, Posted by logu_ii